|
|
Trimethoprim-Sulfamethoxazole Combination
Research News and Information
Definition of 'Trimethoprim-Sulfamethoxazole Combination'This drug combination has proved to be an effective therapeutic agent with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS. Common names: Trimethoprim-Sulfamethoxazole Combination; Trimethoprim Sulfamethoxazole Combination; Centran; Centrin; Co-Trimoxazole; Co Trimoxazole; Cotrimoxazole; Trimethoprim-Sulfamethoxazole; Trimethoprim Sulfamethoxazole; Insozalin; Sulfamethoxazole-Trimethoprim Combination |
Monday, November 23, 2009
Antibiotic prophylaxis and recurrent urinary tract infection in children.
27 Oct 2009
BACKGROUND: Antibiotics are widely administered to children with the intention of preventing urinary tract infection, but adequately powered, placebo-controlled trials regarding efficacy are lacking. This study from four Australian centers examined ... Read more...
13 Oct 2009
BACKGROUND: Solid-organ transplant (SOT) recipients are classically considered to be at increased risk for listeriosis. However, risk factors for this infection have not been assessed. METHODS: We carried out a multicenter, matched case-control ... Read more...
Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole.
30 Aug 2009
A retrospective case-notes audit of 359 HIV-1-infected adult patients with first-episode laboratory-confirmed Pneumocystis jirovecii pneumonia treated with co-trimoxazole (from 1987 adjuvant steroids were used if PaO(2) <9.3 kPa) showed that only ... Read more...
Latest indexed articles for 'Trimethoprim-Sulfamethoxazole Combination'
These are the very latest articles for this heading:
- Antimicrobial prophylaxis for urinary tract infection in children.
27 Oct 2009 - Antibiotic prophylaxis and recurrent urinary tract infection in children.
27 Oct 2009 - Risk factors, clinical features, and outcomes of listeriosis in solid-organ transplant recipients: a matched case-control study.
13 Oct 2009 - Clinical and tomographic features of macular punctate outer retinal toxoplasmosis.
29 Sep 2009 - Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole.
30 Aug 2009 - Rifampin-containing regimens for community-associated skin infection: a hazard without known benefit.
30 Aug 2009 - Stevens-Johnson syndrome and toxic epidermal necrolysis: consequence of treatment of an emerging pathogen.
30 Jul 2009 - Effective Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole once a day twice a week.
30 Jul 2009 - When to start antiretroviral therapy in resource-limited settings.
18 Jul 2009 - Empyema thoracis due to nocardiosis and Mycobacterium tuberculosis mixed infections in an AIDS patient.
29 Jun 2009 - Flare-up of patch test of trimethoprim-sulfamethoxazole (co-trimoxazole) during oral desensitization.
29 Jun 2009 - Trimethoprim/Sulfamethoxazole and azithromycin combination therapy for ocular toxoplasmosis.
29 Jun 2009 - Imaging diagnosis--acquired goitrous hypothyroidism following treatment with trimethoprim sulfamethoxazole.
29 Jun 2009 - Confluent molluscum contagiosum covering the eyelids of an HIV-positive child.
29 Jun 2009 - The role of primary care prescribers in the diagnosis and management of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
29 Jun 2009 - Pulmonary nocardiosis from a tertiary care hospital in Southern India.
29 Jun 2009 - Transconjunctival orbital invasion by methicillin-resistant Staphylococcus aureus.
29 Jun 2009 - Nocardiosis at the turn of the century.
29 Jun 2009 - Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.
27 Jun 2009 - Progressive rash after recent antibiotic exposure.
26 Jun 2009
See a longer list of these articles.
Technical information about 'Trimethoprim-Sulfamethoxazole Combination'
Definition: This drug combination has proved to be an effective therapeutic agent with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.
Chemical name: Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)-, mixt. with 5-((3,4,5-trimethoxyphenyl)methyl)-2,4-pyrimidinediamine
Registry Number: 8064-90-2
Descriptor UI: D015662
Alternative terms: Trimethoprim-Sulfamethoxazole Combination; Trimethoprim Sulfamethoxazole Combination; Centran; Centrin; Co-Trimoxazole; Co Trimoxazole; Cotrimoxazole; Trimethoprim-Sulfamethoxazole; Trimethoprim Sulfamethoxazole; Insozalin; Sulfamethoxazole-Trimethoprim Combination; Sulfamethoxazole Trimethoprim Combination; TMP SMX; TMP-SMX; Trimedin; Trimezole; Eslectin; Bactifor; Bactrim; Biseptol; Biseptol-480; Biseptol 480; Biseptol480; Drylin; Eusaprim; Kepinol; Kepinol Forte; Lescot; Metomide; Oriprim; Septra; Septrin; Sulprim; Sumetrolim; Trimethoprimsulfa; Trimosulfa; Abactrim;
Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;
Pharmacological Action: Anti-Infective Agents, Urinary; Antimalarials; Anti-Infective Agents;
Tree Number: D02.065.884.725.867.500; D02.092.146.807.867.500; D02.886.590.700.725.867.500; D03.383.742.906.500;
History Note: 90
Technical Notes: DF: TMP SMX